image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Audit Committee Compensation Committee Development Advisory Committee Nominating and Corporate Governance Committee
Julia P. Gregory Audit Committee Nominating and Corporate Governance Committee
Lori A. Kunkel, M.D. Compensation Committee Development Advisory Committee
David Lacey, M.D. Compensation Committee Development Advisory Committee
Judith A. Reinsdorf, J.D. Audit Committee Nominating and Corporate Governance Committee
Edward C. Saltzman Compensation Committee Development Advisory Committee
Arthur Sands M.D., Ph.D.
Paul M. Silva Audit Committee Nominating and Corporate Governance Committee
= Chairperson = Member = Chairman of the Board
Print Page
Email Alerts
RSS Feeds
Contact IR